Skip to main content

Press Releases

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Summarizes Compelling Oral Care Study Results

WINNIPEG, MANITOBA -- (Marketwired) -- 03/26/15 -- Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, is pleased to provide a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations.

The dog efficacy study was a controlled, randomized, masked study with 30 dogs each per control and treatment groups. Both groups were fed normal diets, but the treatment group received drinking water containing Kane's oral care water additive at the recommended dosage, while control group received normal water for consumption throughout the study period. On Day 0, dental prophylaxis was performed for each dog and calculus score was confirmed as a score of (0).Then calculus was measured on day 28, 56, 84 of the study period using modified Warrick-Gorrel method.

The mean calculus scores for the Company's oral care water additive were better than the control throughout the study. On day 28, 56, and 84 the calculus score for the water additive was 14.2%, 23.5%, and 25.4% lower than the control group, respectively. The difference in calculus scores between the control and treatment group was statistically significant. In addition, no significant differences were observed between the two treatment groups for either animal body weights or food consumption.

  • 25.4% reduction in calculus (p<0.0229)
  • No change in body weight or food consumption
  • The water additive is an effective first step in pet oral care

"We are very pleased to report our oral care water additive significantly reduces calculus with daily use," stated Gord Froehlich, President and CEO of Kane Biotech. "This is especially significant as a water additive is the first step in a good oral care program and combined with our new products in development Kane Biotech will offer a superior oral care program for your pets."

The dog safety study was a randomized, masked laboratory study with three parallel treatment groups each contained 6 dogs. The product was administered as added to their drinking water at 0, 1 and 5 times the recommended application volume. Dogs were treated for a total of 30 consecutive days. Variables measured included clinical observations, physical examinations, oral assessments, body weights, and clinical pathology that include a comprehensive list of hematology and serum chemistry indices, and coagulation profile measured at regular time points during study period. With the exception of soft feces (noted intermittently for 3 of 6 dogs in the 5 times use rate group) findings documented during clinical observations, physical examinations and oral assessments were within normal limits. Trends were similar across treatment and control groups. Evaluation of clinical pathology indices revealed no group trends or individual effects which were considered treatment-related. In conclusion, the safety study successfully demonstrated the product is safe up to 5 times the recommended usage rate during the study period.

  • Passed comprehensive safety assessment up to 5 times usage rate
  • Contains ingredients that meet Health Canada's LRVHP (Low Risk Veterinary Health Program)

"Better science leads to a healthier mouth and a happier pet and our new standard of oral care technology for pets is the best in the world," stated Gord Froehlich, President and CEO of Kane Biotech. "We are unique in having the only oral care water additive on the market with compelling science and proven efficacy combined with an unprecedented safety profile."

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

StrixNB™, DispersinB®, Aledex®, bluestem™ and coactiv+™ are trademarks of Kane Biotech Inc. All Rights Reserved 2015

Kane Biotech Inc.
Gord Froehlich
President & CEO
204-474-7552 (FAX)

Source: Kane Biotech Inc.